Financial Daily from THE HINDU group of publications
Tuesday, Jul 06, 2004
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Announcements


Orchid gets European drug body nod for Cephradine

Our Bureau

Chennai , July 5

ORCHID Chemicals & Pharmaceuticals on Monday announced that the European regulator, European Directorate for the Quality of Medicines, had approved its manufacturing facility for the bulk drug, Cephradine. The approval, Orchid's eighth such, allows it to export the drug to Europe.

More Stories on : Announcements | Standards & Benchmarks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Tata Steel divests stake in Stewarts & Lloyds

Orchid gets European drug body nod for Cephradine
Astra Pharma fixes floor price of Rs 825 for AstraZeneca open offer
Polaris files counter claim against Indonesian bank — Arbitration proceedings to begin soon
Essar Oil to raise $207 m via FCCB
Ashok Soota to receive CII award
Company secretaries to form global body
SRF clears Rs 12.7-cr proposal to cut gas emission
Employee referrals popular among HR managers
`L&T's young staff need to grow with the company'
DM Wall System to launch new products
Elder Pharma, Reliance Life tie up for skin care products
`Sensex may touch 7,000-mark in six months'
Six Wockhardt units get USFDA approval
Yamaha Motor hopes to break even by next year — To invest Rs 400 cr
GCMMF aims at Rs 500-cr rise in sales
Avery India to focus on top-end machines
Post-Priyamvada Birla era — MP Birla group may be handed over to trust
A turnaround year for Agro Tech Foods
Rajinder Kumar is Ranbaxy's R&D head
Maruti unveils Esteem variant — Prices it Rs 40,000 less

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line